UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) shares saw unusually-strong trading volume on Monday after HC Wainwright upgraded the stock from a neutral rating to a buy rating. HC Wainwright now has a $50.00 price target on the stock. Approximately 2,166,518 shares traded hands during trading, an increase of 119% from the previous session's volume of 989,570 shares.The stock last traded at $14.28 and had previously closed at $12.03.
Several other equities research analysts have also commented on the stock. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target on the stock. Oppenheimer cut their target price on UroGen Pharma from $36.00 to $10.00 and set an "outperform" rating on the stock in a research note on Tuesday, June 3rd. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research note on Thursday. Scotiabank lifted their price objective on shares of UroGen Pharma from $23.00 to $47.00 and gave the company a "sector outperform" rating in a research note on Friday. Finally, Guggenheim increased their target price on shares of UroGen Pharma from $15.00 to $30.00 and gave the company a "buy" rating in a research report on Friday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $28.00.
Check Out Our Latest Report on URGN
Insider Activity
In other UroGen Pharma news, insider Mark Schoenberg sold 5,162 shares of UroGen Pharma stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the transaction, the insider now directly owns 153,378 shares of the company's stock, valued at $1,130,395.86. The trade was a 3.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 5.10% of the stock is currently owned by corporate insiders.
Institutional Trading of UroGen Pharma
Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in UroGen Pharma in the fourth quarter worth about $1,472,000. Lazard Asset Management LLC acquired a new stake in shares of UroGen Pharma in the 4th quarter valued at approximately $67,000. Janus Henderson Group PLC acquired a new stake in UroGen Pharma during the 4th quarter valued at $149,000. ProShare Advisors LLC bought a new position in UroGen Pharma in the 4th quarter valued at about $137,000. Finally, Bank of New York Mellon Corp lifted its holdings in UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock worth $1,001,000 after purchasing an additional 6,430 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.
UroGen Pharma Price Performance
The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The company's 50 day moving average is $8.54 and its 200 day moving average is $10.03. The firm has a market capitalization of $658.96 million, a price-to-earnings ratio of -4.47 and a beta of 0.40.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. On average, equities research analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.
About UroGen Pharma
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
